Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome

Renuka V. Iyer, Sheila N J Sait, Sei Ichi Matsui, Annemarie W. Block, Maurice Barcos, James L Slack, Meir Wetzler, Maria R. Baer

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Massive hyperdiploidy (>50 chromosomes) and tetraploidy (4n) are rare cytogenetic abnormalities in myelocytic malignancies, and their significance is unknown. We report on 11 patients with acute myelocytic leukemia (AML) and two patients with a myelodysplastic syndrome (MDS) with massive hyperdiploidy (10 patients) or tetraploidy (3 patients) seen at our institution over a 12-year period. Eleven patients were male and two were female. Age range was 44-84 years (median, 70 years). Only one AML patient had a previous MDS, and no patient had therapy-related disease. One or more copies of chromosomes 8 and 19 were gained in eight patients each; other frequently gained chromosomes included 13, 15, and 21. Eight patients had structural abnormalities in addition to chromosome gain; del(5q) was most common (five patients). Eleven patients received induction chemotherapy, but only four achieved complete remission. Survival ranged from 1 to 22 months, with a median of 6 months. We conclude that massive hyperdiploidy and tetraploidy are infrequent abnormalities in AML and MDS, are seen primarily in de novo disease in older male patients and are associated with a low remission rate and short survival. Massive hyperdiploidy and tetraploidy define a prognostically unfavorable cytogenetic group in de novo AML.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalCancer Genetics and Cytogenetics
Volume148
Issue number1
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Polyploidy
Tetraploidy
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Chromosomes
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 13
Chromosomes, Human, Pair 8
Induction Chemotherapy
Cytogenetics
Chromosome Aberrations
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. / Iyer, Renuka V.; Sait, Sheila N J; Matsui, Sei Ichi; Block, Annemarie W.; Barcos, Maurice; Slack, James L; Wetzler, Meir; Baer, Maria R.

In: Cancer Genetics and Cytogenetics, Vol. 148, No. 1, 01.01.2004, p. 29-34.

Research output: Contribution to journalArticle

Iyer, Renuka V. ; Sait, Sheila N J ; Matsui, Sei Ichi ; Block, Annemarie W. ; Barcos, Maurice ; Slack, James L ; Wetzler, Meir ; Baer, Maria R. / Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. In: Cancer Genetics and Cytogenetics. 2004 ; Vol. 148, No. 1. pp. 29-34.
@article{977b4379b4a2488c9b511934917d2c7b,
title = "Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome",
abstract = "Massive hyperdiploidy (>50 chromosomes) and tetraploidy (4n) are rare cytogenetic abnormalities in myelocytic malignancies, and their significance is unknown. We report on 11 patients with acute myelocytic leukemia (AML) and two patients with a myelodysplastic syndrome (MDS) with massive hyperdiploidy (10 patients) or tetraploidy (3 patients) seen at our institution over a 12-year period. Eleven patients were male and two were female. Age range was 44-84 years (median, 70 years). Only one AML patient had a previous MDS, and no patient had therapy-related disease. One or more copies of chromosomes 8 and 19 were gained in eight patients each; other frequently gained chromosomes included 13, 15, and 21. Eight patients had structural abnormalities in addition to chromosome gain; del(5q) was most common (five patients). Eleven patients received induction chemotherapy, but only four achieved complete remission. Survival ranged from 1 to 22 months, with a median of 6 months. We conclude that massive hyperdiploidy and tetraploidy are infrequent abnormalities in AML and MDS, are seen primarily in de novo disease in older male patients and are associated with a low remission rate and short survival. Massive hyperdiploidy and tetraploidy define a prognostically unfavorable cytogenetic group in de novo AML.",
author = "Iyer, {Renuka V.} and Sait, {Sheila N J} and Matsui, {Sei Ichi} and Block, {Annemarie W.} and Maurice Barcos and Slack, {James L} and Meir Wetzler and Baer, {Maria R.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/S0165-4608(03)00214-0",
language = "English (US)",
volume = "148",
pages = "29--34",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome

AU - Iyer, Renuka V.

AU - Sait, Sheila N J

AU - Matsui, Sei Ichi

AU - Block, Annemarie W.

AU - Barcos, Maurice

AU - Slack, James L

AU - Wetzler, Meir

AU - Baer, Maria R.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Massive hyperdiploidy (>50 chromosomes) and tetraploidy (4n) are rare cytogenetic abnormalities in myelocytic malignancies, and their significance is unknown. We report on 11 patients with acute myelocytic leukemia (AML) and two patients with a myelodysplastic syndrome (MDS) with massive hyperdiploidy (10 patients) or tetraploidy (3 patients) seen at our institution over a 12-year period. Eleven patients were male and two were female. Age range was 44-84 years (median, 70 years). Only one AML patient had a previous MDS, and no patient had therapy-related disease. One or more copies of chromosomes 8 and 19 were gained in eight patients each; other frequently gained chromosomes included 13, 15, and 21. Eight patients had structural abnormalities in addition to chromosome gain; del(5q) was most common (five patients). Eleven patients received induction chemotherapy, but only four achieved complete remission. Survival ranged from 1 to 22 months, with a median of 6 months. We conclude that massive hyperdiploidy and tetraploidy are infrequent abnormalities in AML and MDS, are seen primarily in de novo disease in older male patients and are associated with a low remission rate and short survival. Massive hyperdiploidy and tetraploidy define a prognostically unfavorable cytogenetic group in de novo AML.

AB - Massive hyperdiploidy (>50 chromosomes) and tetraploidy (4n) are rare cytogenetic abnormalities in myelocytic malignancies, and their significance is unknown. We report on 11 patients with acute myelocytic leukemia (AML) and two patients with a myelodysplastic syndrome (MDS) with massive hyperdiploidy (10 patients) or tetraploidy (3 patients) seen at our institution over a 12-year period. Eleven patients were male and two were female. Age range was 44-84 years (median, 70 years). Only one AML patient had a previous MDS, and no patient had therapy-related disease. One or more copies of chromosomes 8 and 19 were gained in eight patients each; other frequently gained chromosomes included 13, 15, and 21. Eight patients had structural abnormalities in addition to chromosome gain; del(5q) was most common (five patients). Eleven patients received induction chemotherapy, but only four achieved complete remission. Survival ranged from 1 to 22 months, with a median of 6 months. We conclude that massive hyperdiploidy and tetraploidy are infrequent abnormalities in AML and MDS, are seen primarily in de novo disease in older male patients and are associated with a low remission rate and short survival. Massive hyperdiploidy and tetraploidy define a prognostically unfavorable cytogenetic group in de novo AML.

UR - http://www.scopus.com/inward/record.url?scp=0346970934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346970934&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(03)00214-0

DO - 10.1016/S0165-4608(03)00214-0

M3 - Article

C2 - 14697638

AN - SCOPUS:0346970934

VL - 148

SP - 29

EP - 34

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 1

ER -